Therapeutic Treatment Plan Optimization during the COVID-19 Pandemic: A Comprehensive Physicochemical Compatibility Study of Intensive Care Units Selected Drugs.
LC stability-indicating assay method
SARS-CoV-2 pandemic
compatibility study
degradation kinetic
drugs mixtures (Sufentanil, Clonidine, Loxapine, Midazolam, and Ketamine)
intensive care units
Journal
Pharmaceutics
ISSN: 1999-4923
Titre abrégé: Pharmaceutics
Pays: Switzerland
ID NLM: 101534003
Informations de publication
Date de publication:
28 Feb 2022
28 Feb 2022
Historique:
received:
17
01
2022
revised:
25
02
2022
accepted:
25
02
2022
entrez:
26
3
2022
pubmed:
27
3
2022
medline:
27
3
2022
Statut:
epublish
Résumé
The SARS-CoV-2 pandemic has resulted in a dramatic rise of the demand for medical devices and drugs. In this context, an important shortage of programmable syringe pumps, used to administrate different drugs in intensive care units, was seen. The opportunity of administrating combinations of five intensive care units selected drugs (Sufentanil, Clonidine, Loxapine, Midazolam, and Ketamine) was considered. The drug mixtures were studied in a pure form or diluted in NaCl 0.9% or G5%. Twenty-six possible combinations of the five drugs were produced in glass vials or polypropylene syringes and stored at 25 °C for 14 days. The LC method was implemented to study drugs combinations in the presence of the degradation products. The clearness and pH were also monitored. All the 26 possible combinations displayed adequate physicochemical stability at 25 °C: at least 3 days and 7 days, respectively, for the dilution in 0.9% NaCl or glucose 5%, and the pure drug products mixtures. The study provided sufficient stability results, covering the medication administration period of at least three days. The combination of more than two drugs offers the advantage of minimizing the individual doses and reduces unwanted side-effects. Hence, this study opens up the possibility of combining the five drugs in one single syringe, which is useful especially under the current circumstances associated with an important shortage of programmable syringe pumps and pharmaceuticals.
Sections du résumé
BACKGROUND
BACKGROUND
The SARS-CoV-2 pandemic has resulted in a dramatic rise of the demand for medical devices and drugs. In this context, an important shortage of programmable syringe pumps, used to administrate different drugs in intensive care units, was seen. The opportunity of administrating combinations of five intensive care units selected drugs (Sufentanil, Clonidine, Loxapine, Midazolam, and Ketamine) was considered.
METHODS
METHODS
The drug mixtures were studied in a pure form or diluted in NaCl 0.9% or G5%. Twenty-six possible combinations of the five drugs were produced in glass vials or polypropylene syringes and stored at 25 °C for 14 days. The LC method was implemented to study drugs combinations in the presence of the degradation products. The clearness and pH were also monitored.
RESULTS
RESULTS
All the 26 possible combinations displayed adequate physicochemical stability at 25 °C: at least 3 days and 7 days, respectively, for the dilution in 0.9% NaCl or glucose 5%, and the pure drug products mixtures.
CONCLUSIONS
CONCLUSIONS
The study provided sufficient stability results, covering the medication administration period of at least three days. The combination of more than two drugs offers the advantage of minimizing the individual doses and reduces unwanted side-effects. Hence, this study opens up the possibility of combining the five drugs in one single syringe, which is useful especially under the current circumstances associated with an important shortage of programmable syringe pumps and pharmaceuticals.
Identifiants
pubmed: 35335926
pii: pharmaceutics14030550
doi: 10.3390/pharmaceutics14030550
pmc: PMC8952813
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Pharm Weekbl Sci. 1992 Aug 21;14(4):196-200
pubmed: 1437499
Pharm Dev Technol. 2018 Dec;23(10):1067-1076
pubmed: 28990851
Drug Discov Today. 2016 Jul;21(7):1189-95
pubmed: 27240777
Can J Hosp Pharm. 2013 May;66(3):198
pubmed: 23814289
Pharmacol Res Perspect. 2015 Jun;3(3):e00149
pubmed: 26171228
J Pain Symptom Manage. 2004 May;27(5):471-5
pubmed: 15120775
J Sep Sci. 2007 Aug;30(12):1833-8
pubmed: 17638356
J Pharm Biomed Anal. 2000 Aug 15;23(2-3):421-8
pubmed: 10933535
J Pharm Biomed Anal. 2015 Feb;105:74-83
pubmed: 25543285
Am J Health Syst Pharm. 2014 Apr 15;71(8):657-61
pubmed: 24688040
Eur J Pharm Sci. 2003 May;19(1):31-6
pubmed: 12729859
Am J Health Syst Pharm. 2011 Aug 15;68(16):1537-40
pubmed: 21817086